TQB2922

· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for TQB2922, covering 2025-04-25 to 2026-04-21. Get the full timeline:

Most recent: Clinical Trial Update: Clinical Trial of TQB2922 Injection (Subcutaneous Injection) in Patients With Advanced Cancers [Phase 1]